<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02079480</url>
  </required_header>
  <id_info>
    <org_study_id>IM142-003</org_study_id>
    <nct_id>NCT02079480</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects</brief_title>
  <official_title>Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986090 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK)
      and pharmacodynamics (PD) of BMS-986090 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests</measure>
    <time_frame>Up to Day 85 after single dose of BMS-986090</time_frame>
    <description>AE = Adverse event
ECG = Electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of multiple dose measured by incidence, potential significance and clinical importance of AEs, as determined by medical review of AE reports, vital sign measurements, ECGs and results of physical examination and laboratory tests</measure>
    <time_frame>Up to Day 106 after multiple dose of BMS-986090</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of BMS-986090 single dose subcutaneous (SC) and intravenous (IV)</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of single dose BMS-986090 SC and IV</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of single dose BMS-986090 SC and IV</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of single dose BMS-986090 SC and IV</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal serum half-life (T-HALF) of single dose BMS-986090 SC and IV</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT) of single dose BMS-986090 IV</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of single dose BMS-986090 SC</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at terminal phase (Vz) of single dose BMS-986090 IV</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during steady state (Vss) of single dose BMS-986090 IV</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution at terminal phase (Vz/F) of single dose BMS-986090 SC</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute bioavailability (F) of single dose BMS-986090 SC</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of multiple dose BMS-986090 SC</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed serum concentration (Tmax) of multiple dose BMS-986090 SC</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal serum half-life (T-HALF) of multiple dose BMS-986090 SC</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve in one dosing Interval [AUC(TAU)] of multiple dose BMS-986090 SC</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of multiple dose BMS-986090 SC</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration over a dosing interval (Css-avg) of multiple dose BMS-986090 SC</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fluctuation (DF) of multiple dose BMS-986090 SC</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC accumulation index (AI_AUC); ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose of BMS-986090 SC (multiple dose)</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax accumulation index (AI_Cmax); ratio of Cmax at steady state to Cmax after the first dose of BMS-986090 SC (multiple dose)</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of multiple dose BMS-986090 SC</measure>
    <time_frame>Days 1 -106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-KLH immunoglobulin G (IgG) and IgM antibody levels of single dose BMS-986090 SC</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of BMS-986090 following single SC / IV infusion measured by frequency of subjects with positive anti-drug-antibody (ADA) assessment and frequency of subjects who develop positive ADA following a negative baseline</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor occupancy (RO) of BMS-986090 following single SC or IV infusion</measure>
    <time_frame>Days 1 -85</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Healthy Adult Volunteers</condition>
  <arm_group>
    <arm_group_label>Panel 1: BMS-986090 (0.5 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 0.5 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: BMS-986090 (3 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 3 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3: BMS-986090 (10 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 10 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 30 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
And Keyhole limpet hemocyanin (KLH) 1 mg solution single intramuscular dose once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 100 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
And KLH 1 mg solution single intramuscular dose once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 6: BMS-986090 (100 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 100 mg solution single dose intravenously once
OR
Placebo matching with BMS-986090 0 mg solution single dose intravenously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 300 mg solution single dose subcutaneously once
OR
Placebo matching with BMS-986090 0 mg solution single dose subcutaneously once
And KLH 1 mg solution single intramuscular dose once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 8: BMS-986090 (750 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 750 mg solution single dose intravenously once
OR
Placebo matching with BMS-986090 0 mg solution single dose intravenously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 9: BMS-986090 (150 mg) or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986090 150 mg solution subcutaneously once weekly for 4 weeks
OR
Placebo matching with BMS-986090 0 mg solution subcutaneously once weekly for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986090</intervention_name>
    <arm_group_label>Panel 1: BMS-986090 (0.5 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-986090 (3 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-986090 (10 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 6: BMS-986090 (100 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 8: BMS-986090 (750 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 9: BMS-986090 (150 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with BMS-986090</intervention_name>
    <arm_group_label>Panel 1: BMS-986090 (0.5 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 2: BMS-986090 (3 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 3: BMS-986090 (10 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 6: BMS-986090 (100 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 8: BMS-986090 (750 mg) or Placebo</arm_group_label>
    <arm_group_label>Panel 9: BMS-986090 (150 mg) or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keyhole limpet hemocyanin</intervention_name>
    <arm_group_label>Panel 4: BMS-986090 (30 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 5: BMS-986090 (100 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <arm_group_label>Panel 7: BMS-986090 (300 mg) or Placebo + KLH (1 mg)</arm_group_label>
    <other_name>KLH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Healthy male and female (of not childbearing potential), ages 18-45 years, inclusive

          -  BMI 18 to 32 kg/m2, inclusive

        Exclusion Criteria:

        - Any significant acute or chronic medical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parexel Baltimore Early Phase Clinical Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keyhole-limpet hemocyanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

